Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 1, 2009, Pages 92-96

  Talameh, Jasmine A ^a   Rezk, Naser L ^a   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cervicovaginal fluid; Female genital tract; High performance liquid chromatography; Integrase inhibitor; Raltegravir; Solid phase extraction

Indexed keywords

BODY COMPARTMENTS; CLINICAL STUDY; HIV-1 INTEGRASE; INFECTIOUS DISEASE; INTEGRASE; INTEGRASE INHIBITOR; PERCHLORIC ACIDS; REVERSE PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; SAMPLE PREPARATION; SOLID-PHASE EXTRACTION; ULTRA VIOLET DETECTION; ULTRAVIOLET WAVELENGTH;

CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; INORGANIC ACIDS; LIQUIDS; PHARMACOKINETICS; PHASE SEPARATION; VIRUSES;

EXTRACTION;

PERCHLORIC ACID; RALTEGRAVIR;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; GENITAL SYSTEM; HUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION; SPECTRAL SENSITIVITY; ULTRAVIOLET RADIATION; VAGINA DISCHARGE;

ADMINISTRATION, ORAL; BODILY SECRETIONS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENITALIA, FEMALE; HIV INTEGRASE INHIBITORS; HUMANS; LINEAR MODELS; PERCHLORIC ACID; PYRROLIDINONES; SOLID PHASE EXTRACTION; SPECIMEN HANDLING; SPECTROPHOTOMETRY, ULTRAVIOLET;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 71249162709     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.11.015     Document Type: Article

References (10)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global HIV/AIDS epidemic, 2002 (July 2002), World Health Organization, Geneva, Switzerland
2. Hosseinipour M., Cohen M.S., Vernazza P.L., and Kashuba A.D. Clin. Infect. Dis. 34 (2002) 1391
3. Merck & Company-Isentress Prescribing Information, January 2009, p. 1. Available at: http://www.merck.com/product/usa/pi_circulars/i/isentress/isentress_pi.p df (accessed July 21, 2009).
4. Si-Mohamed A., Kazatchine M., Heard I., Goujon C., Prazuck T., Aymard G., Cessot G., Kuo Y.H., Bernard M.C., Diquet B., Malkin J.E., Gutmann L., and Bélec L. J. Infect. Dis. 182 (2000) 112
5. Dumond J.B., Yeh R.F., Patterson K.B., Corbett A.H., Jung B.H., Rezk N.L., Bridges A.S., Stewart P.W., Cohen M.S., and Kashuba A.D. AIDS 21 (2007) 1899
6. Rezk N.L., White N., and Kashuba A.D. Anal. Chim. Acta 628 (2008) 204
7. Owen D.H., and Katz D.F. Contraception 59 (1999) 91
8. Jones A., Talameh J., Patterson K.B., Rezk N.L., Prince H., and Kashuba A.D. Presented at the 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands, April 15-17 (2009)
9. Dumond J.B., Patterson K.B., Pecha A.L., Werner R.E., Andrews E., Damle B., Tressler R., Worsley J., and Kashuba A.D. J. Acquir. Immune Defic. Syndr. 51 (2009) 546
10. U.S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, May 2001. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM070107.pdf (accessed July 23, 2009).